IL235323B - Chimeric proteins to aid in the selection of cells infected with vaccinia virus having a specific recombinant immunoglobulin gene - Google Patents

Chimeric proteins to aid in the selection of cells infected with vaccinia virus having a specific recombinant immunoglobulin gene

Info

Publication number
IL235323B
IL235323B IL235323A IL23532314A IL235323B IL 235323 B IL235323 B IL 235323B IL 235323 A IL235323 A IL 235323A IL 23532314 A IL23532314 A IL 23532314A IL 235323 B IL235323 B IL 235323B
Authority
IL
Israel
Prior art keywords
fusion proteins
vaccinia virus
cells infected
immunoglobulin gene
recombinant vaccinia
Prior art date
Application number
IL235323A
Other languages
English (en)
Hebrew (he)
Other versions
IL235323A0 (en
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of IL235323A0 publication Critical patent/IL235323A0/en
Publication of IL235323B publication Critical patent/IL235323B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL235323A 2012-04-26 2014-10-23 Chimeric proteins to aid in the selection of cells infected with vaccinia virus having a specific recombinant immunoglobulin gene IL235323B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261639046P 2012-04-26 2012-04-26
US201261732776P 2012-12-03 2012-12-03
US13/844,388 US9708601B2 (en) 2012-04-26 2013-03-15 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
PCT/US2013/038497 WO2013163602A1 (en) 2012-04-26 2013-04-26 Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus

Publications (2)

Publication Number Publication Date
IL235323A0 IL235323A0 (en) 2014-12-31
IL235323B true IL235323B (en) 2020-01-30

Family

ID=49477810

Family Applications (1)

Application Number Title Priority Date Filing Date
IL235323A IL235323B (en) 2012-04-26 2014-10-23 Chimeric proteins to aid in the selection of cells infected with vaccinia virus having a specific recombinant immunoglobulin gene

Country Status (16)

Country Link
US (3) US9708601B2 (enExample)
EP (1) EP2841606B1 (enExample)
JP (2) JP6498599B2 (enExample)
KR (1) KR102108589B1 (enExample)
CN (1) CN104520444B (enExample)
AU (1) AU2013251371B2 (enExample)
CA (1) CA2871597C (enExample)
DK (1) DK2841606T3 (enExample)
EA (1) EA028164B1 (enExample)
ES (1) ES2725673T3 (enExample)
IL (1) IL235323B (enExample)
NZ (1) NZ630854A (enExample)
PL (1) PL2841606T3 (enExample)
PT (1) PT2841606T (enExample)
SG (1) SG11201406974YA (enExample)
WO (1) WO2013163602A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2427212T3 (pl) 2009-05-08 2018-02-28 Vaccinex, Inc. Przeciwciała anty cd-100 i sposoby ich zastosowania
EA029023B1 (ru) 2011-10-11 2018-01-31 Вэксинекс, Инк. Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
SG10201902380SA (en) 2013-06-25 2019-04-29 Vaccinex Inc Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
EP3107567A4 (en) * 2014-02-19 2017-10-25 Cangene Corporation Methods of modulating an immune response
KR20170019080A (ko) 2015-08-11 2017-02-21 주식회사 엘티전자 플렉시블 사이니지 장치
EP3402520A4 (en) * 2016-01-14 2019-01-02 BPS Bioscience, Inc. Anti-pd-1 antibodies and uses thereof
EP4059516A1 (en) * 2016-04-22 2022-09-21 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
SG11201900595YA (en) 2016-08-02 2019-02-27 Vaccinex Inc Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
IL270244B2 (en) 2017-05-05 2025-01-01 Vaccinex Inc Antibody against human semaphorin 4D
IL297578A (en) * 2020-05-06 2022-12-01 Vaccinex Inc Integral membrane protein display on extracellular enveloped poxviruses
US20240148903A1 (en) * 2021-03-08 2024-05-09 Nanjing GenScript Biotech Co., Ltd. Delivery of antibody by using dual viral vector system
KR20250022808A (ko) 2022-06-10 2025-02-17 백시넥스 인코포레이티드 복합 막 항원에 특이적인 항체를 선택하는 방법
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445953A (en) 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
AU694519B2 (en) 1994-04-29 1998-07-23 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
ATE407206T1 (de) 1998-11-10 2008-09-15 Univ Rochester Methoden zu herstellung von genbanken
JP2003528605A (ja) 2000-03-28 2003-09-30 ユニヴァーシティー オヴ ロチェスター ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
CA2429544C (en) * 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002062822A2 (en) 2001-02-02 2002-08-15 University Of Rochester Methods of identifying regulator molecules
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1413316A1 (en) 2002-09-27 2004-04-28 Bruno Robert Bifunctional conjugates or fusion proteins
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
CA2548180C (en) 2003-12-04 2014-02-04 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US8022043B2 (en) 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
KR101377116B1 (ko) 2004-08-27 2014-03-24 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 면역 및 자가면역의 조절제로서의 세라마이드 유도체
US7858599B2 (en) 2005-12-30 2010-12-28 Hander Robert W Enhancement of urogenital function
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
DE602008004296D1 (de) 2007-02-14 2011-02-17 Vaccinex Inc Humanisierte anti-cd100-antikörper
JP5357782B2 (ja) 2007-02-21 2013-12-04 バクシネックス インコーポレーティッド 抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節
JP5690593B2 (ja) 2007-12-26 2015-03-25 ヴァクシネックス， インコーポレイテッド 抗ｃ３５抗体併用療法および方法
AU2009303788B2 (en) * 2008-05-28 2015-02-05 Inovio Pharmaceuticals, Inc. Smallpox DNA vaccine and the antigens therein that elicit an immune response
US20100081575A1 (en) 2008-09-22 2010-04-01 Robert Anthony Williamson Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
AU2010203451B2 (en) 2009-01-08 2016-06-30 Albert Einstein College Of Medicine, Inc. Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
PL2427212T3 (pl) 2009-05-08 2018-02-28 Vaccinex, Inc. Przeciwciała anty cd-100 i sposoby ich zastosowania
WO2011110642A2 (en) * 2010-03-10 2011-09-15 Genmab A/S Monoclonal antibodies against c-met
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
SMT201900074T1 (it) * 2010-05-04 2019-02-28 Five Prime Therapeutics Inc Anticorpi che legano csf1r
US8481688B2 (en) * 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
AU2011267869A1 (en) 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
US8603478B2 (en) * 2010-07-06 2013-12-10 Aveo Pharmaceuticals, Inc. Anti-RON antibodies
EP2591090A4 (en) 2010-07-07 2013-12-25 Einstein Coll Med BACTERIAL VACCINES ASSOCIATED WITH CERAMIDE GLYCOLIPIDS AND USES THEREOF
EP2611832B1 (en) 2010-09-02 2017-11-29 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
PT2711023T (pt) 2011-05-13 2017-10-02 Univ Nat Corp Tokyo Medical & Dental Promotor da osteogénese
EA029023B1 (ru) 2011-10-11 2018-01-31 Вэксинекс, Инк. Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
CN104520323B (zh) 2012-03-02 2018-05-04 瓦西尼斯公司 用于治疗b细胞介导的炎性疾病的方法
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
JP6363623B2 (ja) 2013-01-31 2018-07-25 ヴァクシネックス， インコーポレイテッド 免疫グロブリンａのレベルを増大するための方法
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
SG10201902380SA (en) 2013-06-25 2019-04-29 Vaccinex Inc Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
EP4059516A1 (en) 2016-04-22 2022-09-21 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
SG11201900595YA (en) 2016-08-02 2019-02-27 Vaccinex Inc Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
WO2018156509A1 (en) 2017-02-22 2018-08-30 Vaccinex, Inc. Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases
US11572408B2 (en) 2017-03-20 2023-02-07 Vaccinex, Inc. Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent
IL270244B2 (en) 2017-05-05 2025-01-01 Vaccinex Inc Antibody against human semaphorin 4D

Also Published As

Publication number Publication date
JP2019055956A (ja) 2019-04-11
US9708601B2 (en) 2017-07-18
CA2871597A1 (en) 2013-10-31
DK2841606T3 (da) 2019-05-06
CA2871597C (en) 2021-04-20
KR102108589B1 (ko) 2020-05-07
EA028164B1 (ru) 2017-10-31
KR20150009560A (ko) 2015-01-26
PT2841606T (pt) 2019-05-17
ES2725673T3 (es) 2019-09-26
JP2015514811A (ja) 2015-05-21
US20170306318A1 (en) 2017-10-26
US9701958B2 (en) 2017-07-11
PL2841606T3 (pl) 2019-07-31
SG11201406974YA (en) 2014-11-27
AU2013251371A1 (en) 2014-11-13
JP6498599B2 (ja) 2019-04-10
US20160152971A1 (en) 2016-06-02
IL235323A0 (en) 2014-12-31
AU2013251371B2 (en) 2018-01-04
EP2841606A4 (en) 2015-12-30
CN104520444B (zh) 2017-12-12
US20130288927A1 (en) 2013-10-31
WO2013163602A1 (en) 2013-10-31
US10662422B2 (en) 2020-05-26
EA201491965A1 (ru) 2015-03-31
NZ630854A (en) 2017-03-31
EP2841606B1 (en) 2019-01-23
EP2841606A1 (en) 2015-03-04
CN104520444A (zh) 2015-04-15

Similar Documents

Publication Publication Date Title
IL235323A0 (en) Chimeric proteins to aid in the selection of cells infected with vaccinia virus having a specific recombinant immunoglobulin gene
IL285015A (en) Recombinant cell surface capture proteins
LT2925350T (lt) Imunomoduliuojančių fc sulietų baltymų priešvėžinio aktyvumo stiprinimas
PT3744835T (pt) Proteínas de fusão modificadoras do adn e métodos de utilização das mesmas
IL236809A0 (en) Interleukin-10 fusion proteins and their use
EP3689365C0 (en) USE OF LONG-ACTING GLP-1 PEPTIDES
CL2014003210A1 (es) Preparación de fluoruro de litio de alta pureza.
BR112014024675A8 (pt) célula hospedeira recombinante, cultura celular
IL235041A0 (en) Recombinant bacterial host cell for protein expression
SG11201403814RA (en) Production of recombinant proteins with simple glycoforms
IL232645B (en) Recombinant proteins and their therapeutic uses
BR112013029769A2 (pt) levedura recombinante
ZA201406434B (en) Improved harvest operations for recombinant proteins
IL223665B (en) Human antibodies to human cytomegalovirus (cmv) gb protein
EP2804946A4 (en) RECOMBINANT CHO GMT PROTEIN EXPRESSION
HRP20190271T1 (hr) Rekombinantno cjepivo protiv virusa mačje leukemije koje sadrži optimirajući gen proteina omotača virusa mačje leukemije
CO6821887A2 (es) Polipéptido de anticuerpo recombinante anti-cianobasterias, gel del mismo,y método de preparación del mismo
EP2937362A4 (en) RECOMBINANT PROTEIN
ZA201504817B (en) Hiv-1 env-binding antibodies, fusion proteins, and methods of use
AU2012902684A0 (en) Recombinant Viral Vectors and Uses Therefor
AU2011901988A0 (en) Recombinant viral vaccines
AU2012902593A0 (en) Improved Recombinant Viruses

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed